Akari Therapeutics announces establishment of headquarters in Boston

Akari Therapeutics announced the establishment of a Boston Seaport area office that is the company’s U.S. headquarters. The office supports Akari’s current expansion of operations in preparation for the start of enrollment in two registrational nomacopan Phase 3 clinical trials in pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy and the start of PAS-nomacopan clinical trials in geographic atrophy. “Boston is a vibrant epicenter of biotech innovation in the U.S. providing Akari access to world-class talent and other resources as we continue to build our U.S. capabilities, advance our pivotal clinical trials, and work to realize the promise of nomacopan on behalf of patients and our investors,” said Rachelle Jacques, Akari President and CEO. Enrollment in the Phase 3 clinical trials of nomacopan in pediatric and adult HSCT-TMA is expected to begin in late 2023 and 2024, respectively. The start of clinical trials of long-acting PAS-nomacopan as a potential treatment for GA is anticipated in 2024